[开放获取]    白癜风靶向药物临床应用进展及前景

doi:10.35541/cjd.20230509

Abstract

Abstract: 【Abstract】 In recent years, great progress has been made in the research on the pathogenesis of vitiligo, and many new treatment methods and drugs have emerged. Interferon-γ-activated Janus kinase （JAK） signaling and melanocyte regeneration signaling pathways are the most concerned targets in the research on the treatment of vitiligo. This article summarizes the efficacy of current new drugs targeting these pathways and the experience in applying these drugs in the treatment of vitiligo. JAK inhibitors are currently the most promising new drugs for the treatment of vitiligo, and their efficacy can be improved in combination with phototherapy.

Key words: Vitiligo, Janus kinases, Enzyme inhibitors, Tofacitinib, Simvastatin, Alpha-melanocyte stimulating hormone

Li Shuli, Li Chunying. Clinical application of targeted drugs in vitiligo: progress and prospects[J]. Chinese Journal of Dermatology, 2024, 57(1): 12-16.doi:10.35541/cjd.20230509

References ［27］

［1］	Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy［J］. JAMA Dermatol, 2015,151（10）:1110⁃1112. doi: 10.1001/jamadermatol.2015.1520.
［2］	Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure［J］. J Am Acad Dermatol, 2017,77（4）:675⁃682.e1. doi: 10.1016/j.jaad.2017.05.043.
［3］	Kim SR, Heaton H, Liu LY, et al. Rapid repigmentation of vitiligo using tofacitinib plus low⁃dose, narrowband UV⁃B phototherapy［J］. JAMA Dermatol, 2018,154（3）:370⁃371. doi: 10.1001/jamadermatol.2017.5778.
［4］	Fang WC, Chiu SH, Lin SY, et al. Evaluation of low⁃dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy: a pilot study［J］. Photodermatol Photoimmunol Photomed, 2021,37（4）:345⁃347. doi: 10.1111/phpp.12661.
［5］	Gianfaldoni S, Tchernev G, Wollina U, et al. Micro ⁃ focused phototherapy associated to Janus kinase inhibitor: a promising valid therapeutic option for patients with localized vitiligo［J］. Open Access Maced J Med Sci, 2018,6（1）:46⁃48. doi: 10.3889/oamjms.2018.042.
［6］	Fang WC, Lin SY, Huang SM, et al. Low⁃dose tofacitinib with 308⁃nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo［J］. Clin Exp Dermatol, 2022,47（4）:782⁃783. doi: 10.1111/ced.15070.
［7］	Song H, Hu Z, Zhang S, et al. Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real⁃world clinical practice［J］. Dermatol Ther, 2022,35（11）:e15821. doi: 10.1111/dth. 15821.
［8］	Xu Z, Xing X, Xuan Y, et al. Progressive nonsegmental vitiligo successfully treated with oral tofacitinib and narrow⁃band UVB: a case report of 2⁃year follow⁃up［J］. Photodermatol Photoimmunol Photomed, 2023,39（6）:663⁃666. doi: 10.1111/phpp.12900.
［9］	Mobasher P, Guerra R, Li SJ, et al. Open⁃label pilot study of tofacitinib 2% for the treatment of refractory vitiligo［J］. Br J Dermatol, 2020,182（4）:1047⁃1049. doi: 10.1111/bjd.18606.
［10］	McKesey J, Pandya AG. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo［J］. J Am Acad Dermatol, 2019,81（2）:646⁃648. doi: 10.1016/j.jaad.2019.04.032.
［11］	Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata （AA）［J］. J Am Acad Dermatol, 2016,74（2）:370⁃371. doi: 10.1016/j.jaad.2015.09.073.
［12］	Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib［J］. J Am Acad Dermatol, 2017,76（6）:1054⁃1060.e1. doi: 10.1016/j.jaad. 2017.02.049.
［13］	Joshipura D, Alomran A, Zancanaro P, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32⁃week open⁃label extension study with optional narrow⁃band ultraviolet B［J］. J Am Acad Dermatol, 2018,78（6）:1205⁃1207.e1. doi: 10.1016/j.jaad.2018.02.023.
［14］	Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial［J］. Lancet, 2020,396（10244）:110⁃120. doi: 10.1016/S0140⁃6736（20）30609⁃7.
［15］	Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo［J］. N Engl J Med, 2022,387（16）:1445⁃1455. doi: 10.1056/NEJMoa 2118828.
［16］	Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib［J］. Australas J Dermatol, 2020,61（4）:374⁃376. doi: 10.1111/ajd.13348.
［17］	Li X, Sun Y, Du J, et al. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB⁃UVB phototherapy［J］. Clin Cosmet Investig Dermatol, 2023,16:635⁃638. doi: 10.2147/CCID.S396430.
［18］	Pan T, Mu Y, Shi X, et al. Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report［J］. J Dermatolog Treat, 2023,34（1）:2200873. doi: 10.1080/09546634.2023.2200873.
［19］	Su X, Luo R, Ruan S, et al. Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo［J］. J Am Acad Dermatol, 2023:S0190⁃9622（23）02410⁃02416. doi: 10.1016/j.jaad.2023.07.1016.
［20］	Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial［J］. J Am Acad Dermatol, 2023,88（2）:395⁃403. doi: 10.1016/j.jaad.2022.11.005.
［21］	Noël M, Gagné C, Bergeron J, et al. Positive pleiotropic effects of HMG⁃CoA reductase inhibitor on vitiligo［J］. Lipids Health Dis, 2004,3:7. doi: 10.1186/1476⁃511X⁃3⁃7.
［22］	Vanderweil SG, Amano S, Ko WC, et al. A double⁃blind, placebo⁃controlled, phase⁃Ⅱ clinical trial to evaluate oral simvastatin as a treatment for vitiligo［J］. J Am Acad Dermatol, 2017,76（1）:150⁃151.e3. doi: 10.1016/j.jaad.2016.06.015.
［23］	Nguyen S, Chuah SY, Fontas E, et al. Atorvastatin in combination with narrowband UV⁃B in adult patients with active vitiligo: a randomized clinical trial［J］. JAMA Dermatol, 2018,154（6）:725⁃726. doi: 10.1001/jamadermatol.2017.6401.
［24］	Niezgoda A, Winnicki A, Kosmalski T, et al. The evaluation of vitiligous lesions repigmentation after the administration of atorvastatin calcium salt and simvastatin⁃acid sodium salt in patients with active vitiligo （EVRAAS）, a pilot study: study protocol for a randomized controlled trial［J］. Trials, 2019,20（1）:78. doi: 10.1186/s13063⁃018⁃3168⁃4.
［25］	Grimes PE, Hamzavi I, Lebwohl M, et al. The efficacy of afamelanotide and narrowband UV⁃B phototherapy for repigmen⁃tation of vitiligo［J］. JAMA Dermatol, 2013,149（1）:68⁃73. doi: 10.1001/2013.jamadermatol.386.
［26］	Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV⁃B phototherapy for the treatment of vitiligo: a randomized multicenter trial［J］. JAMA Dermatol, 2015,151（1）:42⁃50. doi: 10.1001/jamadermatol.2014.1875.
［27］	Toh J, Chuah SY, Jhingan A, et al. Afamelanotide implants and narrow⁃band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians［J］. J Am Acad Dermatol, 2020,82（6）:1517⁃1519. doi: 10.1016/j.jaad.2020.01.035.

[1]	LIN Neng-xing, ZHANG Li-xia, HUANG Chang-zheng, CHEN Hong-xiang, TU Ya-ting. The Mutation of IR Gene in the mtr System and Multiple Antibiotic Resistance of Neisseria gonorrhoeae[J]. Chinese Journal of Dermatology, 2005, 38(12): 719 -721 .
[2]	WENG Yan, LIU Jin-hong, YU Qiao-yi, MA Ping, YANG Yi, LIAO Song-lin. Fibromucinous Primary Cutaneous T-Cell Lymphoma Rich in Blood Vessels: A Case Report[J]. Chinese Journal of Dermatology, 2005, 38(12): 729 -731 .
[3]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 762 -763 .
[4]	. [J]. Chinese Journal of Dermatology, 2005, 38(12): 774 .
[5]	李靖华, 周晓鸿. [J]. Chinese Journal of Dermatology, 2005, 38(12): 775 .
[6]	CHEN Hong-xiang, LIN Neng-xing, HUANG Chang-zheng, LI Jia-wen, LIU Hou-jun, TU Ya-ting. Construction of a Prokaryotic Expression Plasmid Encoding the mtrC Gene of N.gonorrhoeae and Its Expression in E.coli[J]. Chinese Journal of Dermatology, 2005, 38(11): 674 -676 .
[7]	孙青, 徐从高. [J]. Chinese Journal of Dermatology, 2005, 38(11): 696 -697 .
[8]	. [J]. Chinese Journal of Dermatology, 2005, 38(11): 705 .
[9]	孙志平, 邱实, 谭升顺. [J]. Chinese Journal of Dermatology, 2005, 38(11): 676 .
[10]	赵景辉, 马东来, 孙秋宁, 肖雨, 邱红惠. [J]. Chinese Journal of Dermatology, 2005, 38(11): 711 .

[1]	Dai Yeqin, Song Xiuzu. Application of hair follicle transplantation and follicular cell suspension transplantation in the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230274-e0230274.
[2]	Sun Weiwei, Chen Jianru, Li Shuli, Gao Tianwen, Li Chunying . Analysis of depression-like behavioral performances of mouse models of vitiligo [J]. Chinese Journal of Dermatology, 2024, 57(2): 147-154.
[3]	Wang Tao, Wu Yi, Jin Hong, Dai Yeqin, Peng Jianzhong, Xu Ai′e, Song Xiuzu. Efficacy of electrolysis of depigmented hair combined with hair follicle transplantation in the treatment of 25 cases of vitiligo-associated leukotrichia: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(1): 46-49.
[4]	Guliziba·Tuersun, Qu Yuanyuan. New advances in the treatment of vitiligo with JAK-STAT inhibitors [J]. Chinese Journal of Dermatology, 2024, 57(1): 71-75.
[5]	Chen Hui, Li Bing, Li Chunying, Guo Weinan . Comparison of the efficacy of water jet-assisted dermabrasion versus electric dermabrasion in combination with suction blister epidermal grafting in the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2024, 57(1): 43-45.
[6]	He Kaiqiao, Li Shuli, Li Baizhang, Liu Ling, Li Chunying. Clinical observation of repigmentation patterns in patients with vitiligo treated with phototherapy and analysis of their influencing factors [J]. Chinese Journal of Dermatology, 2024, 57(1): 23-28.
[7]	Ma Jingjing, Kang Pan, Guo Sen, Jian Zhe, Li Chunying, Li Shuli. Expression patterns of transcription factor TFAP2B in epidermal melanocytes in healthy individuals and vitiligo patients [J]. Chinese Journal of Dermatology, 2024, 57(1): 29-33.
[8]	Zhang Qian, Zhang Jin′e, Guo Sen, Song Pu, Gao Lin, Li Chunying. Comparison of the efficacy of fractional CO2 laser combined with topical delivery of fluorouracil versus compound betamethasone injections in the treatment of vitiligo: a clinical observation [J]. Chinese Journal of Dermatology, 2024, 57(1): 34-38.
[9]	Xuan Yijie, Yang Yiwen, Wang Chen, Xu Zhongyi, Xiang Leihong, Zhang Chengfeng. Investigation of clinical factors influencing the response to systemic glucocorticoid treatment in patients with progressive non-segmental vitiligo [J]. Chinese Journal of Dermatology, 2024, 57(1): 17-22.
[10]	Li Chunying, Chen Jianru, Li Shuli. Metabolic reconfiguration in vitiligo: progress and future [J]. Chinese Journal of Dermatology, 2024, 57(1): 8-11.
[11]	Zeng Rui, Xu Xiulian. Narrow-band ultraviolet B phototherapy combined with other therapies for the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2024, 57(1): 75-78.
[12]	Wang Haoyang, Wang Yidan, Lu Yan . Role of neurogenic inflammatory factors in the pathogenesis of vitiligo [J]. Chinese Journal of Dermatology, 2024, 57(1): 78-81.
[13]	Dai Leheng, Hu Wen, Zhang Kunjie, Kang Xiaojing. Protective effects of isorhamnetin against H2O2-induced mitochondrial structural and functional damage in HaCaT cells [J]. Chinese Journal of Dermatology, 2023, 56(9): 857-861.
[14]	Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723.
[15]	Jia Weixue, Li Chengrang. Comparison of Chinese and international guidelines and consensus for the diagnosis and treatment of vitiligo [J]. Chinese Journal of Dermatology, 2023, 56(5): 471-475.

Clinical application of targeted drugs in vitiligo: progress and prospects

PDF

Knowledge

Abstract

Cite this article

share this article

References ［27］

Related Articles 15

Metrics

Comments

Recommended 10